AIDS Malignancy Clinical Trials Consortium (Limited Competition U01)

The summary for the AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	AIDS Malignancy Clinical Trials Consortium (Limited Competition U01)
	CFDA Number:	93.393
	CFDA Description:	Cancer Cause and Prevention Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-CA-10-502
	Document Type:	Grants Notice
	Funding Instrument Type:	Cooperative Agreement
	Posted Date:	Dec 24, 2009
	Creation Date:	Dec 24, 2009
	Original Closing Date for Applications:	Mar 03, 2010
	Current Closing Date for Applications:	Mar 03, 2010
	Archive Date:	Apr 03, 2010
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$4,680,000
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: The eligibility to apply in response to this limited competition FOA is limited to the current AMC Group Chair recipient institution (U01CA121947).
Grant Description: Purpose. The purpose of this limited competition funding opportunity announcement (FOA) is to continue support of the research activities of AIDS Malignancy Consortium which are: 1) design, development, and evaluation of clinical interventions for the prevention and treatment of malignancies in patients with HIV infection; 2) development of more effective management and therapeutics for HIV-associated malignancies; 3) investigation of the biology of HIV malignancies within the context of clinical trials; 4) management of issues of international importance in HIV-associated-malignancies; and 5) distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations. The award will provide subcontracts for a coordinating center, core sites, affiliate sites, network laboratories and a statistical center. Sites will receive patient care costs on a capitation basis and for laboratory correlative studies, clinical pharmacology and international studies. The group will have at least four scientific disease-oriented working groups (WG) - KS, lymphoma, HPV-associated cancers, and non-AIDS-Defining Cancers (NADCs) Working Groups . Mechanism of Support. This FOA will use the NIH U01 cooperative agreement award mechanism. Funds Available and Anticipated Number of Awards. It is anticipated that $ 4.68 million for year one will be available for this initiative, and one application is expected to be awarded.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ca-10-502.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Alliance of Glycobiologists for Detection of Cancer (U01); • Cancer Target Discovery and Development (CTDD) Network (U01); • Community Clinical Oncology Program Research Bases (U10); • Minority-Based Community Clinical Oncology Program Groups (U10); • Community Clinical Oncology Program Groups (U10); • Pilot Studies in Pancreatic Cancer; • CANCER PREVENTION RESEARCH SMALL GRANT PROGRAM; • MOLECULAR TARGETS FOR NUTRIENTS IN PROSTATE CANCER PREVENTION; • Cancer Prevention Research Small Grant Program (R03); • Pilot Studies in Pancreatic Cancer (R03)